Trial
NCT03248479
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Hematological Malignancies
Intervention
Magrolimab
Why stopped
This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-17